Form 8-K - Current report:
SEC Accession No. 0001193125-24-269400
Filing Date
2024-12-03
Accepted
2024-12-03 07:10:52
Documents
15
Period of Report
2024-12-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d858884d8k.htm   iXBRL 8-K 24759
2 EX-99.1 d858884dex991.htm EX-99.1 16377
6 GRAPHIC g858884g1203041425224.jpg GRAPHIC 3978
  Complete submission text file 0001193125-24-269400.txt   179564

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eltx-20241203.xsd EX-101.SCH 2878
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eltx-20241203_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eltx-20241203_pre.xml EX-101.PRE 11726
18 EXTRACTED XBRL INSTANCE DOCUMENT d858884d8k_htm.xml XML 3796
Mailing Address 451 D STREET, 5TH FLOOR BOSTON MA 02210
Business Address 451 D STREET, 5TH FLOOR BOSTON MA 02210 (857) 209-0050
Elicio Therapeutics, Inc. (Filer) CIK: 0001601485 (see all company filings)

EIN.: 113430072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39990 | Film No.: 241521056
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)